Moderna Joins Top S&P 500 Firms as Stock Value Triples

Bloomberg2021-07-22

(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile. The move caps the drugmaker’s transformation from an early-stage biotech to...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Guardian91
    2021-07-22
    Guardian91
    Vaccination is more of a necessity for the next 5 years till the world has more or less achieved herd immunity. Moderna can hold the spot for awhilebut it need to innovate or have other high efficiency drugs for any further long term growth potential. ?
  • Shank88
    2021-07-22
    Shank88
    The constant need for vaccines and boostershots will Ensure consistent profitability. Cheap? Maybe not.
  • 377tkr
    2021-07-22
    377tkr
    How true?
  • xiaochan
    2021-07-22
    xiaochan
    Wow! Go go go!! 
  • TriciaChang
    2021-07-22
    TriciaChang
    Ok
  • QqSM
    2021-07-22
    QqSM
    Great summary. Thanks
Leave a comment
15